Literature DB >> 3317066

Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.

K J Tracey1, Y Fong, D G Hesse, K R Manogue, A T Lee, G C Kuo, S F Lowry, A Cerami.   

Abstract

Bacterial infection of the mammalian bloodstream can lead to overwhelming sepsis, a potentially fatal syndrome of irreversible cardiovascular collapse (shock) and critical organ failure. Cachectin, also known as tumour necrosis factor, is a macrophage-derived peptide hormone released in response to bacterial lipopolysaccharide, and it has been implicated as a principal mediator of endotoxic shock, although its function in bacterial sepsis is not known. Anaesthetized baboons were passively immunized against endogenous cachectin and subsequently infused with an LD100 dose of live Escherichia coli. Control animals (not immunized against cachectin) developed hypotension followed by lethal renal and pulmonary failure. Neutralizing monoclonal anti-cachectin antibody fragments (F(ab')2) administered to baboons only one hour before bacterial challenge protected against shock, but did not prevent critical organ failure. Complete protection against shock, vital organ dysfunction, persistent stress hormone release and death was conferred by administration of antibodies 2 h before bacterial infusion. These results indicate that cachectin is a mediator of fatal bacteraemic shock, and suggest that antibodies against cachectin offer a potential therapy of life-threatening infection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3317066     DOI: 10.1038/330662a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  566 in total

1.  The tyrosine kinase inhibitor tyrphostin AG126 reduces the development of acute and chronic inflammation.

Authors:  S Cuzzocrea; M C McDonald; E Mazzon; D Siriwardena; G Calabrò; D Britti; G Mazzullo; A De Sarro; A P Caputi; C Thiemermann
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

Review 2.  Innate immunity and inflammation: a transcriptional paradigm.

Authors:  J Hawiger
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

3.  Rapid and sensitive assay of tumor necrosis factor-alpha gene transcription.

Authors:  X Zhang; J Ye; L Wang; J Manosroi; X Shi; Y Rojanasakul
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

4.  Production of polyclonal antibodies to feline tumor necrosis factor.

Authors:  C M Otto; F Niagro; R A McGraw; C A Rawlings
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

5.  Hematopoietic stem-progenitor cells restore immunoreactivity and improve survival in late sepsis.

Authors:  Laura Brudecki; Donald A Ferguson; Deling Yin; Gene D Lesage; Charles E McCall; Mohamed El Gazzar
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

6.  New approaches to sepsis: molecular diagnostics and biomarkers.

Authors:  Konrad Reinhart; Michael Bauer; Niels C Riedemann; Christiane S Hartog
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

7.  Anti-inflammatory effects of hyperoside in human endothelial cells and in mice.

Authors:  Sae-Kwang Ku; Wei Zhou; Wonhwa Lee; Min-Su Han; MinKyun Na; Jong-Sup Bae
Journal:  Inflammation       Date:  2015-04       Impact factor: 4.092

8.  Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo.

Authors:  Andreas A Erdmann; Zhan-Guo Gao; Unsu Jung; Jason Foley; Todd Borenstein; Kenneth A Jacobson; Daniel H Fowler
Journal:  Blood       Date:  2005-03-03       Impact factor: 22.113

9.  The Physiological Role of Tumor Necrosis Factor in Human Immunity and Its Potential Implications in Spinal Manipulative Therapy: A Narrative Literature Review.

Authors:  Liang Zhang; Chao Hua Yao
Journal:  J Chiropr Med       Date:  2016-05-26

10.  Orientin inhibits HMGB1-induced inflammatory responses in HUVECs and in murine polymicrobial sepsis.

Authors:  Hayoung Yoo; Sae-Kwang Ku; Taeho Lee; Jong-Sup Bae
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.